AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure. AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like Receptor 7 agonist vesatolimod (GS-9620) in HIV-infected individuals. Read the full press release here